HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 62.8%

Neg 0% Neu 0% Pos 62.8%

HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.